FindTrial
Sign In

Efficacy of Thrombomodulin Combined with ILR Dynamic Changes in Risk Stratification and Prognostic Evaluation of Sepsis.

Efficacy of Thrombomodulin Combined with ILR Dynamic Changes in Risk Stratification and Prognostic Evaluation of Sepsis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109844
Enrollment
Unknown
Registered
2025-09-25
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Non-survivor group:NA
Survivor group:NA

Sponsors

Chongqing Emergency Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older. 2. Patients with confirmed infection foci and a definitive diagnosis of sepsis. 3. Patients who voluntarily participated in this clinical study and provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Under 18 years of age. 2. Patients with infection but a SOFA score < 2 points are classified as non-septic. 3. Patients with malignant tumors. 4. Patients with severe liver disease (Child-Pugh class C). 5. Patients who declined to participate in the study.

Design outcomes

Primary

MeasureTime frame
Lymphocyte count;Interleukin-10 (IL-10);Thrombomodulin;—

Countries

China

Contacts

Public ContactBin Liu

Chongqing Emergency Medical Center

408992584@qq.com+86 23 63692150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026